|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2008-6-18
|
|
pubmed:abstractText |
We evaluated the acute and late toxicity after high-dose intensity-modulated radiotherapy (IMRT) with fiducial marker-based position verification for prostate cancer. Between 2001 and 2004, 331 patients with prostate cancer received 76 Gy in 35 fractions using IMRT combined with fiducial marker-based position verification. The symptoms before treatment (pre-treatment) and weekly during treatment (acute toxicity) were scored using the Common Toxicity Criteria (CTC). The goal was to score late toxicity according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) scale with a follow-up time of at least three years. Twenty-two percent of the patients experienced pre-treatment grade > or = 2 genitourinary (GU) complaints and 2% experienced grade 2 gastrointestinal (GI) complaints. Acute grade 2 GU and GI toxicity occurred in 47% and 30%, respectively. Only 3% of the patients developed acute grade 3 GU and no grade > or = 3 GI toxicity occurred. After a mean follow-up time of 47 months with a minimum of 31 months for all patients, the incidence of late grade 2 GU and GI toxicity was 21% and 9%, respectively. Grade > or = 3 GU and GI toxicity rates were 4% and 1%, respectively, including one patient with a rectal fistula and one patient with a severe hemorrhagic cystitis (both grade 4). In conclusion, high-dose intensity-modulated radiotherapy with fiducial marker-based position verification is well tolerated. The low grade > or = 3 toxicity allows further dose escalation if the same dose constraints for the organs at risk will be used.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-10758303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-11020558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-11042576,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-11690676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-12128107,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-12128109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-12865177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15465140,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15465194,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15519775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15749008,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15752881,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15936549,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15939547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-15989996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-16160131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-16648499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-16814954,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-16952647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-17141903,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-17222931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-17379434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-17398026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-17513059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-18082588,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-7713792,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18495016-9054871
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1748-717X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
15
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18495016-Aged,
pubmed-meshheading:18495016-Aged, 80 and over,
pubmed-meshheading:18495016-Brachytherapy,
pubmed-meshheading:18495016-Gastrointestinal Tract,
pubmed-meshheading:18495016-Humans,
pubmed-meshheading:18495016-Male,
pubmed-meshheading:18495016-Middle Aged,
pubmed-meshheading:18495016-Prostatic Neoplasms,
pubmed-meshheading:18495016-Radiation Injuries,
pubmed-meshheading:18495016-Radiotherapy, Intensity-Modulated,
pubmed-meshheading:18495016-Radiotherapy Dosage,
pubmed-meshheading:18495016-Radiotherapy Planning, Computer-Assisted,
pubmed-meshheading:18495016-Urogenital System
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
|
|
pubmed:affiliation |
Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. i.m.lips@umcutrecht.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
